Oculus Prepares to Initiate Clinical Study for Use of Microcyn® Hydrogel in Management of Scars Based Upon FDA-Reviewed Protocol  |   Oculus Innovative Sciences (OCLS) products...... too effective and too large of a market for the big pharmaceutical companies to ignore.   |   CEO Hoji Alimi's Video Interview with BioMedReports  |   Oculus Reports Fiscal Third Quarter 2012 Financial Results  |   Fiscal Third Quarter 2012 Financial Results and Conference Call Scheduled for February 2nd  |   Oculus Reports Record First Quarter Financial Results  |   Oculus Announces a Multi-Year Licensing Agreement with Eloquest Healthcare® for Microcyn®-Based Wound Care Products  |   AmDerma Pharmaceuticals Exercises Option to License Rights to Microcyn®-Based Acne Drug Candidate  |   Reports Record Fourth Quarter, Beating Quarterly Guidance; and Reports Year-End Revenue for Fiscal Year Ended March 31, 2011  |   Amneal and Oculus Announce Broad Multi-Market, Multi-Product Collaboration for Microcyn®-Based Drugs and Devices  |   Announces New FDA 510K Clearance for Microcyn-Based Dermatology HydroGel for Management of Atopic Dermatitis, Radiation Dermatitis and Other Skin Dermatoses  |   Launches Microcyn® Dermatology HydroGel for Relief of Pain and Itch into U.S. Dermatology Healthcare Market  |